Aridica Corporation
Aridica Corporation is dedicated to advancing immune system research and clinical applications by providing high-quality, automated immune cell isolation solutions. Their mission is to accelerate the development of diagnostics and next-generation therapeutics by simplifying and standardizing the process of immune cell separation. With a focus on automation, reliability, scalability, and sustainability, Aridica aims to empower researchers and clinicians to unlock the full potential of the immune system for improved health outcomes.
Industries
N/A
Nr. of Employees
small (1-50)
Aridica Corporation is currently seeking investment
Aridica Corporation is seeking a seed investment in the range of 1m-5m
Products
Automated PBMC separation platform (prototype stage)
An automated laboratory instrument and consumable system intended to separate PBMCs from whole blood with standardized, push-button workflows that reduce hands-on time and operator variability while enabling parallel processing.
Automated PBMC separation platform (prototype stage)
An automated laboratory instrument and consumable system intended to separate PBMCs from whole blood with standardized, push-button workflows that reduce hands-on time and operator variability while enabling parallel processing.
Expertise Areas
- Immune cell isolation and PBMC preparation
- Laboratory automation for sample processing
- Microfluidic device development
- Point-of-care blood analysis development
Key Technologies
- Laboratory automation systems
- Microfluidic cartridge-based systems
- PBMC/immune cell separation methods
- Dry multiplexed immunoassay approaches
Key People
News & Updates
Recognized as one of the most promising innovators in life science tools and diagnostics, Aridica was selected for the prestigious BioTools Innovator Accelerator program, joining a top-tier global cohort.
Awarded $238,000 by the Colorado OEDIT Advanced Industries Accelerator program to advance the development of their blood separation technology.
Aridica was chosen from over 400 applicants as one of 31 startups to join the 2025 BioTools Innovator Accelerator, a global program for life science tools and diagnostics companies. The program offers mentorship, investor exposure, and the opportunity to compete for $300,000 in non-dilutive cash prizes. Aridica will participate in events such as the Innovator Summit and Capstone Event.
Aridica was awarded a $238,000 Early-Stage Capital and Retention grant from the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Accelerator program. The grant supports the development, prototyping, and testing of Aridica’s blood separation technology, preparing the company for commercialization and growth in Colorado.
Recognized as one of the most promising innovators in life science tools and diagnostics, Aridica was selected for the prestigious BioTools Innovator Accelerator program, joining a top-tier global cohort.
Awarded $238,000 by the Colorado OEDIT Advanced Industries Accelerator program to advance the development of their blood separation technology.
Aridica was chosen from over 400 applicants as one of 31 startups to join the 2025 BioTools Innovator Accelerator, a global program for life science tools and diagnostics companies. The program offers mentorship, investor exposure, and the opportunity to compete for $300,000 in non-dilutive cash prizes. Aridica will participate in events such as the Innovator Summit and Capstone Event.
Aridica was awarded a $238,000 Early-Stage Capital and Retention grant from the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Accelerator program. The grant supports the development, prototyping, and testing of Aridica’s blood separation technology, preparing the company for commercialization and growth in Colorado.